U.S. markets closed
  • S&P 500

    3,315.57
    +34.51 (+1.05%)
     
  • Dow 30

    27,288.18
    +140.48 (+0.52%)
     
  • Nasdaq

    10,963.64
    +184.84 (+1.71%)
     
  • Russell 2000

    1,496.96
    +11.71 (+0.79%)
     
  • Crude Oil

    39.55
    +0.24 (+0.61%)
     
  • Gold

    1,904.30
    -6.30 (-0.33%)
     
  • Silver

    24.51
    +0.12 (+0.50%)
     
  • EUR/USD

    1.1714
    -0.0059 (-0.50%)
     
  • 10-Yr Bond

    0.6640
    -0.0070 (-1.04%)
     
  • GBP/USD

    1.2733
    -0.0085 (-0.66%)
     
  • USD/JPY

    104.9140
    +0.2340 (+0.22%)
     
  • BTC-USD

    10,552.84
    +115.12 (+1.10%)
     
  • CMC Crypto 200

    215.09
    +1.33 (+0.62%)
     
  • FTSE 100

    5,829.46
    +25.17 (+0.43%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m. EDT.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of lupus nephritis (Anticipated PDUFA date: January 22, 2021) and evaluating voclosporin ophthalmic solution (VOS) in a Phase 2/3 study for the treatment of dry eye syndrome. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005227/en/

Contacts

Investor & Corporate Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com